Honeywell International Inc
Total Consideration
$14.1M
Purchase-Price Allocation
Goodwill
$1.5M
Intangibles
−$1.5M
Liabilities Assumed
−$3.5M
Pro-Forma Combined Entity
Revenue
$54.9M
Net Income
+$5.5M
INNOVATIVE SOLUTIONS AND SUPPORT, INC. — Key Metrics
2 years of history · ending 2025-09-30 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
M-Score (Beneish; >-1.78 flags risk)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Turnover & Efficiency Analysis (days)
Expense Ratios
Working Capital Analysis
Valuation Multiples
Cash-Flow Multiples
Enterprise Value Multiples
52-Week Range
Trailing Returns
ROIC vs WACC
Yields
Capital Deployment Yields
Liquidity & Leverage Ratios
Earnings Quality (OCF/NI · FCF/NI · Sloan Accruals)
EPS (Diluted)
$1
Book Value Per Share
$4
Free Cash Flow Per Share
$0
Cash Per Share
$0
Revenue Per Share
$5
OCF Per Share
$1
Return on Equity
28.1%
Return on Assets
16.8%
Return on Invested Capital
19.5%
Debt to Equity
0.34
Current Ratio
3.04
Quick Ratio
1.50
Asset Turnover
0.91
Days Sales Outstanding
56.10
Days Payables Outstanding
29.83
Days Inventory On Hand
215.09
Cash Conversion Cycle
241.36
R&D / Revenue
4.7%
SBC / Revenue
2.8%
Capex / Revenue
7.7%
Working Capital
$34M
Net Current Asset Value
$12M
Invested Capital
$86M
OCF / Net Income
0.85
FCF / Net Income
0.43
Accruals Ratio (Sloan)
2.2%
Net Debt
$19M
Net Debt / EBITDA
0.80
Interest Coverage
11.63
Cash Coverage
7.71
Dividend Coverage
—
Capex Coverage
2.04
Tangible Common Equity
$34M
TCE / Total Assets
33.2%
Goodwill / Total Assets
6.5%
NOPAT
$16M
Cash ROIC
8.4%
WC / Revenue
40.4%
Capex / D&A
1.74
Reinvestment Rate
13.8%
Total Payout Ratio
—
Asset Growth vs Revenue Growth
-53.1%
Revenue 5Y CAGR
31.3%
EPS 5Y CAGR
25.3%
FCF 5Y CAGR
9.8%
EBITDA 5Y CAGR
49.6%
Book Value 5Y CAGR
18.4%
Stock Price (FY-end)
$12
Market Cap
$223M
P/E Ratio
14.25
P/S Ratio
2.64
P/B Ratio
3.45
P/TB Ratio
6.49
P/OCF Ratio
16.74
P/FCF Ratio
32.79
Enterprise Value
$242M
EV / EBITDA
10.15
EV / Sales
2.87
EV / FCF
35.59
FCF Yield
3.0%
Dividend Yield
—
Shareholder Yield
-1.0%
Buyback Yield
—
R&D Yield
1.8%
Capex Yield
2.9%
Dividend Per Share
—
DPS YoY Growth
—
Operating Leverage
1.37
Graham Number
$8
Shares Variation (YoY)
2.0%
Beta (5Y)
0.66
Cost of Equity
7.8%
Cost of Debt (after tax)
6.2%
WACC
7.6%
ROIC - WACC Spread
11.9%
52W High
$20
52W Low
$6
Trailing Return 1Y
95.2%
Trailing Return 5Y
101.0%
F-Score (Piotroski)
5.00
M-Score (Beneish)
-1.95
Z-Score (Altman)
5.68
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.
EPS — Consensus vs Actual
Revenue — Consensus vs Actual
Stock Price on Earnings Dates
INNOVATIVE SOLUTIONS AND SUPPORT, INC. — Effective Tax Rate ReconciliationNEW
Bridges from the federal statutory rate (21% post-TCJA) to the effective tax rate via the issuer's tax-note reconciliation lines. Sourced from EffectiveIncomeTaxRateReconciliation* flat CompanyFacts concepts. Conditional lines (R&D credits, FDII, SBC, valuation allowance, etc.) only render when the issuer discloses them. Persistent divergence between accrual tax expense and cash taxes paid is a leading signal for deferred-tax buildup.
Effective Rate Trend
| Reconciliation Line | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Federal Statutory Rate | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% | 21.00% |
| State & Local Income Taxes | 0.60% | 0.60% | 11.80% | 0.40% | 1.10% | 2.20% |
| Foreign Rate Differential | — | — | — | — | — | — |
| Other Adjustments | 0.00% | 0.00% | -0.50% | 0.10% | 0.00% | — |
| R&D Tax Credits | — | — | — | — | — | — |
| Valuation Allowance Change | -47.90% | -47.90% | -6.40% | -0.10% | -0.10% | -1.50% |
| Effective Tax Rate | -27.40% | -27.40% | 24.70% | 21.10% | 20.90% | 21.70% |
Cash vs Accrual
| Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Income Tax Expense (Accrual) | −$1.1M | −$1.1M | $1.8M | $1.6M | $1.9M | $4.3M |
| Income Taxes Paid (Cash) | $1.1K | $1.1K | $531.5K | $1.9M | — | — |
INNOVATIVE SOLUTIONS AND SUPPORT, INC. — M&A AcquisitionsNEW
Per-deal acquisition disclosures sourced from us-gaap:BusinessAcquisitionAxis dimensional XBRL. Each card surfaces the deal's purchase-price allocation (goodwill vs intangibles vs liabilities), contingent consideration (unpaid earn-outs), and pro-forma combined-entity numbers. Probability-of-Success (PoS) factor on biotech targets is the ASC 805 contingent-consideration valuation — higher = closer to commercialization, higher implied target value.